La vendita allo scoperto per Humble Gr dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Humble Gr. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Humble Gr (OTC:HMBAF) Azioni, Report sulle vendite allo scoperto

Humble Group AB is a Swedish foodtech and FMCG group. Humble targets the foodtech, eco, sustainability and vegan segments to drive organic growth and acquisitions in the various business units: brands, distribution, manufacturing and ingredients, and R&D. Its technical solutions facilitate new formulations and recipes that improve the taste and consistency of the next generation of sugar-reduced, sustainable, and vegan products.

Humble Group AB

InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) affirms FY2025 sales outlook from $815.00 million-865.00 million to $815.00 million-865.00 million.

News

Guidance

INNV

InnovAge Holding Affirms FY2025 Sales Guidance to $815.00M-865.00M  VS Est. 844.27M

MCHP

Microchip Sees Q3 2024 Net Sales $1.025B-$1.095B

SMCI

Super Micro Computer Expects To Report Prelim. Q1 Net Sales $5.9B-$6B (Prior $6B-$7B) , Non-GAAP EPS $0.75-$0.76 (Prior $0.67-$0.83)

trivago (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVG#NASDAQ">TRVG</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.02 by 300 percent. The company reported quarterly sales of $160.565 million which beat the analyst consensus estimate of $154.280 million by 4.07 percent. This is a 6.55 percent decrease over sales of $171.825 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

TRVG

trivago Q3 2024 GAAP EPS $(0.04) Misses $0.02 Estimate, Sales $160.565M Beat $154.280M Estimate

2024 Outlook
The company now expects:
<ul>
<li>Adjusted EBITDA, excluding reportable catastrophes6, to increase low double-digits, led by strong growth in Global Housing, with modest growth in Global Lifestyle.</li>
<li>Adjusted earnings, excluding reportable catastrophes, per diluted share6, to increase mid- to high-teens. Note: The metrics included within the company's outlook are non-GAAP financial measures and the company believes that it cannot, without unreasonable efforts, forecast certain information needed to reconcile to the GAAP measures, the probable significance of which cannot be determined. More information can be found in the Non-GAAP Financial Measures section.</li>
</ul>

Assurant Sees FY24 Adjusted EBITDA, Excluding Reportable Catastrophes, To Increase Low Double-Digits, Led By Strong Growth In Global Housing, With Modest Growth In Global Lifestyle; Adjusted Earnings, Excluding Reportable Catastrophes, Per Diluted Share, To Increase Mid- To High-Teens

InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $205.14 million which beat the analyst consensus estimate of $203.33 million by 0.89 percent. This is a 12.42 percent increase over sales of $182.49 million the same period last year.

InnovAge Holding Q1 EPS $(0.04), Inline, Sales $205.14M Beat $203.33M Estimate

Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $2.52 by 19.05 percent. This is a 30.07 percent decrease over earnings of $4.29 per share from the same period last year. The company reported quarterly sales of $2.97 billion which beat the analyst consensus estimate of $2.94 billion by 0.94 percent. This is a 6.98 percent increase over sales of $2.77 billion the same period last year.

Assurant Q3 Adj $3.00 Beats $2.52 Estimate, Sales $2.97B Beat $2.94B Estimate

Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.43 by 6.98 percent. The company reported quarterly sales of $1.164 billion which beat the analyst consensus estimate of $1.152 billion by 1.01 percent. This is a 48.36 percent decrease over sales of $2.254 billion the same period last year.

Microchip Technology Q2 2025 Adj. EPS $0.46 Beats $0.43 Estimate, Sales $1.164B Beat $1.152B Estimate

Infinera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFN#NASDAQ">INFN</a>) reported quarterly sales of $354.40 million which missed the analyst consensus estimate of $402.87 million by 12.03 percent. This is a 9.68 percent decrease over sales of $392.37 million the same period last year.

INFN

Infinera Q3 Sales $354.40M Miss $402.87M Estimate

CTKB

Cytek Biosciences Sees FY24 Revenue $203M-$210M Vs $203.937M; Sees 5-9% Revenue Growth

US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.68 by 1.47 percent. This is a 11.29 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $168.033 million which beat the analyst consensus estimate of $164.381 million by 2.22 percent. This is a 12.02 percent increase over sales of $150.007 million the same period last year.

USPH

US Physical Therapy Q3 2024 Adj. EPS $0.69 Beats $0.68 Estimate, Sales $168.033M Beat $164.381M Estimate

LUMN

Lumen Technologies Continues To Expect FY24 Adjusted EBITDA Of $3.9B - $4.0B, Net Cash Interest Of $1.15B - $1.25B

Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) reported quarterly earnings of $3.42 per share which beat the analyst consensus estimate of $2.93 by 16.72 percent. The company reported quarterly sales of $253.912 million which missed the analyst consensus estimate of $278.980 million by 8.99 percent. This is a 11.73 percent increase over sales of $227.250 million the same period last year.

GPOR

Gulfport Energy Q3 2024 Adj. EPS $3.42 Beats $2.93 Estimate, Sales $253.912M Miss $278.980M Estimate

Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) lowers FY2024 sales outlook from $60.00 million-90.00 million to $15.00 million.

EOSE

Eos Energy Enterprises Lowers FY2024 Sales Guidance from $60.00M-90.00M to $15.00M  VS Est. 62.33M

Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.21 by 328.57 percent. This is a 221.43 percent increase over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $110.71 million which beat the analyst consensus estimate of $76.11 million by 45.46 percent. This is a 964.81 percent increase over sales of $10.40 million the same period last year.

MGNX

Macrogenics Q3 EPS $0.90 Beats $0.21 Estimate, Sales $110.71M Beat $76.11M Estimate

Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) reported quarterly earnings of $0.29 per share which missed the analyst consensus estimate of $0.34 by 14.71 percent. This is a 34.09 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $102.527 million which beat the analyst consensus estimate of $101.944 million by 0.57 percent. This is a 9.61 percent decrease over sales of $113.431 million the same period last year.

FORR

Forrester Res Q3 2024 Adj. EPS $0.29 Misses $0.34 Estimate, Sales $102.527M Beat $101.944M Estimate

B&G Foods Sees FY24 Net Sales $1.920B-$1.950B Vs $1.951B Est.; Adj. Diluted EPS $0.67-$0.77

Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.02) by 150 percent. The company reported quarterly sales of $51.500 million which beat the analyst consensus estimate of $50.696 million by 1.59 percent. This is a 7.29 percent increase over sales of $48.000 million the same period last year.

Cytek Biosciences Q3 2024 GAAP EPS $0.01 Beats $(0.02) Estimate, Sales $51.500M Beat $50.696M Estimate

Full year fiscal 2025 guidance:2
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">Current</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$2,369</td>
<td colspan="1" rowspan="1">$2,391</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating margin3</td>
<td colspan="1" rowspan="1">23.0&nbsp;%</td>
<td colspan="1" rowspan="1">23.2&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EPS</td>
<td colspan="1" rowspan="1">$5.78</td>
<td colspan="1" rowspan="1">$5.87</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP4</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted revenue</td>
<td colspan="1" rowspan="1">$2,353</td>
<td colspan="1" rowspan="1">$2,375</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted operating margin</td>
<td colspan="1" rowspan="1">22.7&nbsp;%</td>
<td colspan="1" rowspan="1">22.8&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>
<a href="https://mma.prnewswire.com/media/2549531/JKHY_Key_Call_Outs___Q1_FY25.html"><img src="https://mma.prnewswire.com/media/2549531/JKHY_Key_Call_Outs___Q1_FY25.jpg" alt="Key Call-Outs" /></a>

JKHY

Jack Henry & Associates Sees FY25 EPS $5.78-$5.87 Vs $5.83 Est.; Revenue $2.353B-$2.375B Vs $2.37B Est.

Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) narrows FY2024 sales outlook from $495.00 million-525.00 million to $500.00 million-510.00 million.

Comments

Humble Gr

Vendite allo scoperto

Humble Gr (OTC:HMBAF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO